Navigation Links
AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
Date:11/6/2008

TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically-integrated pharmaceutical company with major operations in China and the U.S., today announced its newly appointed Chairman and CEO Mr. Douglas MacLellan will present at Rodman & Renshaw's Annual Global Investment Conference taking place on Wednesday, November 12th, 2008 at the New York Palace Hotel in New York City.

Mr. MacLellan will provide an informative overview of AMDL's core business and growth strategy for its China specialty pharmaceuticals, in-vitro diagnostics and cancer therapeutic divisions. The Company has an aggressive and focused approach to capitalize on these three market sectors, positioning AMDL as one of most rapidly growing and highly-opportunistic micro-cap investment prospects in the vertically-integrated, specialty pharmaceutical sector.

In 2008 alone, AMDL met numerous operational milestones which include: securing more than $25 million in sales contracts for its best-selling HPE anti-aging product line; expanding AMDL's overall revenue opportunity for HPE by launching additional HPE product formulations; and successfully securing US FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic test. The ELISA DR-70(R) FDP cancer diagnostic test is the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.

Attendees wishing to learn more about the Company can attend Mr. MacLellan's presentation which is scheduled at 9:55 a.m. EST in the Henry Salon, 5th Floor of the New York Palace Hotel. Additionally, interested investors can visit the Company's corporate website at http://www.amdl.com or contact AMDL's investor relations department at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 400 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
2. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
3. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
4. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
5. AMDL, Inc. Announces Strategic Realignment
6. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
7. AMDL, Inc. Closes Private Placement of Convertible Notes
8. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
11. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):